Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Nam Hoon | - |
dc.contributor.author | Kim, Dong-Lim | - |
dc.contributor.author | Kim, Kyeong Jin | - |
dc.contributor.author | Kim, Nan Hee | - |
dc.contributor.author | Choi, Kyung Mook | - |
dc.contributor.author | Baik, Sei Hyun | - |
dc.contributor.author | Kim, Sin Gon | - |
dc.date.accessioned | 2021-09-03T05:54:06Z | - |
dc.date.available | 2021-09-03T05:54:06Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83390 | - |
dc.description.abstract | Background: Glycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor, vildagliptin, or a thiazolidinedione, pioglitazone, on glycemic variability and oxidative stress in patients with type 2 diabetes. Methods: In this open label, randomised, active-controlled, pilot trial, individuals who were inadequately controlled with metformin monotherapy were assigned to either vildagliptin (50 mg twice daily, n=17) or pioglitazone (15 mg once daily, n=14) treatment groups for 16 weeks. Glycemic variability was assessed by calculating the mean amplitude of glycemic excursions (MAGE), which was obtained from continuous glucose monitoring. Urinary 8-iso prostaglandin F2 alpha, serum oxidised low density lipoprotein, and high-sensitivity C-reactive protein were used as markers of oxidative stress or inflammation. Results: Both vildagliptin and pioglitazone significantly reduced glycated hemoglobin and mean plasma glucose levels during the 16-week treatment. Vildagliptin also significantly reduced the MAGE (from 93.8 +/- 38.0 to 70.8 +/- 19.2 mg/dL, P=0.046), and mean standard deviation of 24 hours glucose (from 38 +/- 17.3 to 27.7 +/- 6.9, P=0.026); however, pioglitazone did not, although the magnitude of decline was similar in both groups. Markers of oxidative stress or inflammation including urinary 8-iso prostaglandin F2a did not change after treatment in both groups. Conclusion: In this 16-week treatment trial, vildagliptin, but not pioglitazone, reduced glycemic variability in individuals with type 2 diabetes who was inadequately controlled with metformin monotherapy, although a reduction of oxidative stress markers was not observed. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ENDOCRINE SOC | - |
dc.subject | ACUTE GLUCOSE FLUCTUATIONS | - |
dc.subject | POSTPRANDIAL HYPERGLYCEMIA | - |
dc.subject | COMPLICATIONS | - |
dc.subject | MELLITUS | - |
dc.subject | HYPOGLYCEMIA | - |
dc.subject | INHIBITION | - |
dc.subject | ACTIVATION | - |
dc.title | Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Nam Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Nan Hee | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Mook | - |
dc.contributor.affiliatedAuthor | Baik, Sei Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Sin Gon | - |
dc.identifier.doi | 10.3803/EnM.2017.32.2.241 | - |
dc.identifier.scopusid | 2-s2.0-85023195883 | - |
dc.identifier.wosid | 000407811300012 | - |
dc.identifier.bibliographicCitation | ENDOCRINOLOGY AND METABOLISM, v.32, no.2, pp.241 - 247 | - |
dc.relation.isPartOf | ENDOCRINOLOGY AND METABOLISM | - |
dc.citation.title | ENDOCRINOLOGY AND METABOLISM | - |
dc.citation.volume | 32 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 241 | - |
dc.citation.endPage | 247 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002231219 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | ACUTE GLUCOSE FLUCTUATIONS | - |
dc.subject.keywordPlus | POSTPRANDIAL HYPERGLYCEMIA | - |
dc.subject.keywordPlus | COMPLICATIONS | - |
dc.subject.keywordPlus | MELLITUS | - |
dc.subject.keywordPlus | HYPOGLYCEMIA | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordAuthor | Glycemic variability | - |
dc.subject.keywordAuthor | Dipeptidyl-peptidase IV inhibitors | - |
dc.subject.keywordAuthor | Thiazolidinediones | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
dc.subject.keywordAuthor | type 2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.